Direkt zum Inhalt
Merck

Fortfahren mit

F0806

Factor IX human

aqueous glycerol solution, ≥145 units/mg protein

Synonym(e):

Christmas factor, Plasma thromboplastin component

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

Ansicht ändern
PackungsgrößeSKUVerfügbarkeitPreis
100 μg
Warenkorb auf Verfügbarkeit prüfen
€ 365,00

Über diesen Artikel

CAS-Nummer:
UNSPSC Code:
12352202
NACRES:
NA.61
MDL number:
Form:
aqueous glycerol solution
Biological source:
human
Mol wt:
55 kDa

€ 365,00


Warenkorb auf Verfügbarkeit prüfen

Großbestellung anfragen
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten


biological source

human

Quality Level

form

aqueous glycerol solution

specific activity

≥145 units/mg protein

mol wt

55 kDa

technique(s)

ligand binding assay: suitable

UniProt accession no.

shipped in

wet ice

storage temp.

−20°C

Gene Information

human ... F9(2158)

General description

Factor IX is a 55 kDa single chain vitamin K-dependent plasma zymogen which plays a key role in the intrinsic and extrinsic blood coagulation systems.

Application

Factor IX is plasma zymogen key to blood coagulation systems. It has been used in studies of portal vein thrombosis (PVT) in hepatocellular carcinoma (HCC). It has been found that abnormalities in factor IX contribute to PVT in HCC patients. Additionally, it has been used in studies of changes in the coagulation system in patients with inflammatory bowel disease (IBD).

Physical form

Aqueous solution containing 50% (v/v) glycerol

Other Notes

One unit is equivalent to the Factor IX activity in 1.0 mL of normal human plasma at pH 7.4 at 37 °C.
View this factors role in the Coagulation Cascade

Disclaimer

RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 1

Dieser Artikel
233279233480F0931
biological source

human

biological source

human plasma

biological source

-

biological source

human

technique(s)

ligand binding assay: suitable

technique(s)

-

technique(s)

-

technique(s)

ligand binding assay: suitable

form

aqueous glycerol solution

form

liquid

form

liquid

form

solution

mol wt

55 kDa

mol wt

-

mol wt

-

mol wt

168 kDa

UniProt accession no.

P00740

UniProt accession no.

-

UniProt accession no.

-

UniProt accession no.

P12259

shipped in

wet ice

shipped in

wet ice

shipped in

wet ice

shipped in

wet ice


Lagerklasse

10 - Combustible liquids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)



Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen


Verwandter Inhalt

Instructions


Continuous Active State of Coagulation System in Patients With Nonthrombotic Inflammatory Bowel Disease.
Alkim H., et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (2011)
Double trouble: Duchenne muscular dystrophy and hemophilia.
Muge Gokce et al.
Pediatric blood & cancer, 60(3), 525-525 (2012-12-21)
Mariko Yamamoto et al.
[Rinsho ketsueki] The Japanese journal of clinical hematology, 54(3), 300-304 (2013-05-17)
This report describes the successful management of neurosurgical procedures with continuous infusion of recombinant factor IX (rFIX). A 1-year-old boy with severe hemophilia B was administered prophylactic therapy with rFIX after intracranial bleeding. We found the enlargement of an arachnoid



Global Trade Item Number

SKUGTIN
F0806-100UG04061838031044

Questions

Reviews

No rating value

Active Filters